NFSG
PVLA

Newbridge Financial Services Group’s Palvella Therapeutics PVLA Stock Holding History

Newbridge Financial Services Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100
Closed -$31K – 1635
2021
Q2 		$31K Hold
100
– – 0.02% 625
2021
Q1 		$21K Hold
100
– – 0.02% 686
2020
Q4 		$20K Hold
100
– – 0.02% 548
2020
Q3 		$17K Buy
+100
New +$22.8K 0.02% 552

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newbridge Financial Services Group's PVLA Position: Q3 2021 in Review

Newbridge Financial Services Group sold out of Palvella Therapeutics (PVLA) in Q3 2021, closing a stake of 100 shares — an estimated $31K sold.

Newbridge Financial Services Group first reported a position in PVLA in Q3 2020 and held it in 4 quarters. The position peaked at $31K in Q2 2021. 75 funds tracked by Wall St. Rank hold PVLA as of Q3 2021.

  • Newbridge Financial Services Group reported no remaining Palvella Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Newbridge Financial Services Group sold 100 Palvella Therapeutics shares in Q3 2021, an estimated $31K.
  • Newbridge Financial Services Group first reported a position in Palvella Therapeutics in Q3 2020 and held it in 4 quarters.
  • Newbridge Financial Services Group's Palvella Therapeutics position peaked at $31K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2021.

Based on Newbridge Financial Services Group's 13F filing for Q3 2021, filed 27 Oct 2021.